Biogen Inc.

06/23/2021 | Press release | Distributed by Public on 06/23/2021 14:12

EISAI and Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation for LECANEMAB (BAN2401), an Anti-Amyloid Beta Protofibril Antibody for the Treatment of[...]